BACKGROUND: The latest cholesterol guidelines have shifted focus from achieving low-density lipoprotein cholesterol (LDL-C) targets toward statin use and intensity guided by atherosclerotic cardiovascular disease (ASCVD) risk. METHODS: Statin use and intensity were evaluated in 5,905 statin-eligible primary or secondary prevention patients from 138 PALM Registry practices. RESULTS: Overall, 74.7% of eligible adults were on statins; only 42.4% were on guideline-recommended intensity. Relative to primary prevention patients, ASCVD patients were more likely to be on a statin (83.6% vs 63.4%, P<.0001) and guideline-recommended intensity (47.3% vs 36.0%, P<.0001). Men were more likely than women to be prescribed recommended intensity for primary (odds ratio [OR] 1.87, 95% CI 1.49-2.34) and secondary (OR 1.47, 95% CI 1.26-1.70) prevention. In primary prevention, increasing age, diabetes, obesity, hypertension, and lower 10-year ASCVD risk were associated with increased odds of receiving recommended intensity. Among ASCVD patients, those with coronary artery disease were more likely to be on recommended intensity than cerebrovascular or peripheral vascular disease patients (OR 1.71, 95% CI 1.41-2.09), as were those seen by cardiologists (OR 1.43, 95% CI 1.12-1.83). Median LDL-C levels were highest among patients not on statins (124.0 mg/dL) and slightly higher among those on lower-than-recommended intensity compared with recommended-therapy recipients (88.0 and 84.0 mg/dL, respectively; P≤.0001). CONCLUSIONS: In routine contemporary practice, 1 in 4 guideline-eligible patients was not on a statin; less than half were on the recommended statin intensity. Untreated and undertreated patients had significantly higher LDL-C levels than those receiving guideline-directed statin treatment.
BACKGROUND: The latest cholesterol guidelines have shifted focus from achieving low-density lipoprotein cholesterol (LDL-C) targets toward statin use and intensity guided by atherosclerotic cardiovascular disease (ASCVD) risk. METHODS: Statin use and intensity were evaluated in 5,905 statin-eligible primary or secondary prevention patients from 138 PALM Registry practices. RESULTS: Overall, 74.7% of eligible adults were on statins; only 42.4% were on guideline-recommended intensity. Relative to primary prevention patients, ASCVD patients were more likely to be on a statin (83.6% vs 63.4%, P<.0001) and guideline-recommended intensity (47.3% vs 36.0%, P<.0001). Men were more likely than women to be prescribed recommended intensity for primary (odds ratio [OR] 1.87, 95% CI 1.49-2.34) and secondary (OR 1.47, 95% CI 1.26-1.70) prevention. In primary prevention, increasing age, diabetes, obesity, hypertension, and lower 10-year ASCVD risk were associated with increased odds of receiving recommended intensity. Among ASCVD patients, those with coronary artery disease were more likely to be on recommended intensity than cerebrovascular or peripheral vascular diseasepatients (OR 1.71, 95% CI 1.41-2.09), as were those seen by cardiologists (OR 1.43, 95% CI 1.12-1.83). Median LDL-C levels were highest among patients not on statins (124.0 mg/dL) and slightly higher among those on lower-than-recommended intensity compared with recommended-therapy recipients (88.0 and 84.0 mg/dL, respectively; P≤.0001). CONCLUSIONS: In routine contemporary practice, 1 in 4 guideline-eligible patients was not on a statin; less than half were on the recommended statin intensity. Untreated and undertreated patients had significantly higher LDL-C levels than those receiving guideline-directed statin treatment.
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Michael Szarek; John Tsai Journal: JAMA Date: 2005-11-16 Impact factor: 56.272
Authors: Salim S Virani; LeChauncy D Woodard; David J Ramsey; Tracy H Urech; Julia M Akeroyd; Tina Shah; Anita Deswal; Biykem Bozkurt; Christie M Ballantyne; Laura A Petersen Journal: Am J Cardiol Date: 2014-10-12 Impact factor: 2.778
Authors: John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger Journal: N Engl J Med Date: 2005-03-08 Impact factor: 91.245
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Ann Marie Navar; Tracy Y Wang; Xiaojuan Mi; Jennifer G Robinson; Salim S Virani; Veronique L Roger; Peter W F Wilson; Anne C Goldberg; Eric D Peterson Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Michael C Honigberg; Bradley S Lander; Vinit Baliyan; Maeve Jones-O'Connor; Emma W Healy; Jan-Erik Scholtz; John T Nagurney; Udo Hoffmann; Brian B Ghoshhajra; Pradeep Natarajan Journal: JACC Cardiovasc Imaging Date: 2019-07-17
Authors: Zak Loring; Peter Shrader; Larry A Allen; Rosalia Blanco; Paul S Chan; Michael D Ezekowitz; Gregg C Fonarow; James V Freeman; Bernard J Gersh; Kenneth W Mahaffey; Gerald V Naccarelli; Karen Pieper; James A Reiffel; Daniel E Singer; Benjamin A Steinberg; Laine E Thomas; Eric D Peterson; Jonathan P Piccini Journal: Am Heart J Date: 2019-11-08 Impact factor: 4.749
Authors: Michael G Nanna; Ann Marie Navar; Pearl Zakroysky; Qun Xiang; Anne C Goldberg; Jennifer Robinson; Veronique L Roger; Salim S Virani; Peter W F Wilson; Joseph Elassal; L Veronica Lee; Tracy Y Wang; Eric D Peterson Journal: JAMA Cardiol Date: 2018-08-01 Impact factor: 14.676
Authors: Angela Lowenstern; Ann Marie Navar; Shuang Li; Salim S Virani; Anne C Goldberg; Michael J Louie; L Veronica Lee; Eric D Peterson; Tracy Y Wang Journal: Am J Cardiol Date: 2019-01-04 Impact factor: 2.778
Authors: Ann Marie Navar; Tracy Y Wang; Shuang Li; Xiaojuan Mi; Zhuokai Li; Jennifer G Robinson; Salim S Virani; Eric D Peterson Journal: Circ Cardiovasc Qual Outcomes Date: 2021-01-13
Authors: Charles Muiruri; Amy Corneli; Linda Cooper; Carrie Dombeck; Shamea Gray; Chris T Longenecker; Eric G Meissner; Nwora Lance Okeke; April C Pettit; Teresa Swezey; Joseph Vicini; Gerald S Bloomfield Journal: BMC Health Serv Res Date: 2022-05-09 Impact factor: 2.908
Authors: Corey K Bradley; Tracy Y Wang; Shuang Li; Jennifer G Robinson; Veronique L Roger; Anne C Goldberg; Salim S Virani; Michael J Louie; L Veronica Lee; Eric D Peterson; Ann Marie Navar Journal: J Am Heart Assoc Date: 2019-04-02 Impact factor: 5.501
Authors: Christopher P Cannon; James A de Lemos; Robert S Rosenson; Christie M Ballantyne; Yuyin Liu; Qi Gao; Tamara Palagashvilli; Shushama Alam; Katherine E Mues; Deepak L Bhatt; Mikhail N Kosiborod Journal: JAMA Cardiol Date: 2021-06-16 Impact factor: 14.676